Neuroimaging and Molecular Biomarkers for Dementia
Polyakova T. A., Arablinsky A. V.
Neuroscience and Behavioral Physiology
Vol.49, Issue4, P. 406-412
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.1007/s11055-019-00747-7
Аннотация:
The development of laboratory diagnostic and neuroimaging methods allows a number of biomarkers to be detected, improving the in-life diagnosis of a very diverse set of types of dementia (Alzheimer’s disease, Lewy body dementia, vascular dementia). Currently, molecular biomarkers in the cerebrospinal fluid (CSF) for detection of Alzheimer’s disease have the greatest diagnostic sensitivity and specificity. At the same time, structural changes detected on MRI scans are more significant for prognosticating the development of changes in the cognitive domain. Cerebral microbleeds provide an additional accessible marker increasing the diagnostic significance of leukoaraiosis and providing evidence of cerebral amyloid angiopathy or hypertensive microangiopathy, especially in cases of mixed pathology and severe cognitive deficit. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Ключевые слова:
Alzheimer’s disease; Lewy body dementia; molecular biomarkers; neuroimaging; vascular dementia
acetylcholinesterase; amyloid beta protein[1-42]; biological marker; C reactive protein; clusterin; Alzheimer disease; Article; brain analysis; brain hemorrhage; brain region; cerebrospinal fluid; clinical practice; cognition; computer assisted tomography; dementia; diagnostic test accuracy study; differential diagnosis; diffuse Lewy body disease; disease severity; human; image processing; leukoaraiosis; microangiopathy; neuroimaging; neurologic disease assessment; nuclear magnetic resonance imaging; positron emission tomography; prognosis; sensitivity and specificity; single photon emission computed tomography; vascular amyloidosis
Язык текста: Английский
ISSN: 1573-899X
Polyakova T. A.
Arablinsky A. V.
Полякова Т. А.
Араблинскy А. В.
Neuroimaging and Molecular Biomarkers for Dementia
Текст визуальный непосредственный
Neuroscience and Behavioral Physiology
Springer New York Consultants Bureau
Vol.49, Issue4 P. 406-412
2019
Статья
Alzheimer’s disease Lewy body dementia molecular biomarkers neuroimaging vascular dementia
acetylcholinesterase amyloid beta protein[1-42] biological marker C reactive protein clusterin Alzheimer disease Article brain analysis brain hemorrhage brain region cerebrospinal fluid clinical practice cognition computer assisted tomography dementia diagnostic test accuracy study differential diagnosis diffuse Lewy body disease disease severity human image processing leukoaraiosis microangiopathy neuroimaging neurologic disease assessment nuclear magnetic resonance imaging positron emission tomography prognosis sensitivity and specificity single photon emission computed tomography vascular amyloidosis
The development of laboratory diagnostic and neuroimaging methods allows a number of biomarkers to be detected, improving the in-life diagnosis of a very diverse set of types of dementia (Alzheimer’s disease, Lewy body dementia, vascular dementia). Currently, molecular biomarkers in the cerebrospinal fluid (CSF) for detection of Alzheimer’s disease have the greatest diagnostic sensitivity and specificity. At the same time, structural changes detected on MRI scans are more significant for prognosticating the development of changes in the cognitive domain. Cerebral microbleeds provide an additional accessible marker increasing the diagnostic significance of leukoaraiosis and providing evidence of cerebral amyloid angiopathy or hypertensive microangiopathy, especially in cases of mixed pathology and severe cognitive deficit. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.